The Novo Nordisk Fund wants to establish new, extensive lab facilities at Denmark’s Technical University (DTU) in Lyngby.
The new facilities will be called the Novo Nordisk Foundation Cellerator and will be constructed as a partner company with focus on knowledge sharing and cooperation.
The facilities will consist of a GMP production areas for cell therapy in a class B and C clean room operating with mobile processing equipment and single-use technology. Further, there is a lab floor, an office floor, entrance with a common area as well as a basement for storage. The facility will work as an independant unit with its own IT system, where the establishment is a part of the project.
The lab facilities will help researchers with final development and up scaling of new cell therapies so that they can be tested on humans.
The cell therapy can be converted to ordinary forms of treatment for humans with severe diseases. Among other things, they can be helpful for chronic heart failure, Parkinsons disease, kidney diseases, type 1 diabetes and several forms of cancer.
Some hospitals in Denmark already have the opportunity to manufacture cell therapy products, however, only in a small scale. Therefore, Novo Nordisk’s new lab will be the first one able to do it in a scale of this size. Also, it will also be the first lab to gather as many expertises and services under one roof. Namely, it will support all cell therapies based on embryonic stem cells, induced pluripotent stem cells and multipotent stem cells.
It is necessary to deviate from the current local plan if the construction plans is to be realised. Lyngby-Taarbæk Municipality has approved this deviation.
The construction is expected to be begun in Q3 2024 and should be ready for operation in Q3 2027.
Has this project caught your interest? Book a free demo of Projektagenten.
